Claes Karlsson

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan et al. · The Lancet Oncology · 2015 · 408 citations

Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia, Medicine +9

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid et al. · Nature Cancer · 2022 · 120 citations · Full text

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Jeanette Lundin, Anna Porwit‐MacDonald, Eva Rossmann et al. · Leukemia · 2004 · 118 citations

Hematological Malignancy, Lymphoid Neoplasia, Subcutaneous Alemtuzumab +11

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Graeme Fraser, Paula Cramer, Rodrigo Santucci Alves da Silva et al. · Leukemia · 2018 · 116 citations · Full text

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Maria Winqvist, Anna Asklid, Per Andersson et al. · Haematologica · 2016 · 114 citations · Full text

Immunology, Pathology, Pharmacotherapy +17